Coca-Cola (KO), Procter & Gamble (PG), Johnson & Johnson (JNJ), PepsiCo (PEP), and Colgate-Palmolive (CL) are Dividend Kings—each has raised its annual dividend for at least 50 consecutive years. This track record signals durable business models, but performance and valuation differ significantly across the group.
Procter & Gamble leads with a 70-year streak. Johnson & Johnson has maintained 64 years of increases. PepsiCo's run stands at 54 years, the shortest on this list. All five also qualify as Dividend Aristocrats (25 consecutive years of increases).
The four consumer staples players—KO, PG, PEP, CL—benefit from consistent demand for essential goods regardless of economic conditions. Johnson & Johnson, a diversified healthcare company with pharmaceutical and medical device exposure, operates in a sector where spending is often non-discretionary, potentially offering even greater resilience.
Recent results expose meaningful divergence. In Q3 2026, Coca-Cola reported 7 percent organic sales growth—more than double PepsiCo's 3.1 percent. Procter & Gamble and Colgate-Palmolive both posted roughly 4 percent organic growth in their most recent quarters.
Yields tell the story for income investors. Coca-Cola yields 2.2 percent paired with superior sales momentum. PepsiCo yields 4.1 percent, appealing to value-oriented buyers accepting slower organic growth for current income. Procter & Gamble yields 2.5 percent versus Colgate-Palmolive's 2.1 percent, giving P&G a modest edge for yield seekers in the staples space. Johnson & Johnson's 1.9 percent yield is the lowest here, but its 64-year dividend streak is unmatched within healthcare, making it the sector's most reliable income play.
The choice hinges on your priority: chase Coca-Cola for growth with respectable yield, grab PepsiCo for elevated income, or anchor a healthcare allocation with Johnson & Johnson's proven consistency.
